DK2176220T3 - Pyrrolidin-2-on-derivater som androgenreceptormodulatorer. - Google Patents

Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.

Info

Publication number: DK2176220T3
Authority: DK; Denmark
Prior art keywords: pyrrolidin; derivatives; androgen receptor; receptor modulators; modulators
Prior art date: 2007-08-07

Application number

DK08792430.4T

Other languages

English (en)

Inventor

Atsushi Hasuoka

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-07

Filing date

2008-08-06

Publication date

2013-06-10

2008-08-06 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2013-06-10 Application granted granted Critical

2013-06-10 Publication of DK2176220T3 publication Critical patent/DK2176220T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK08792430.4T 2007-08-07 2008-08-06 Pyrrolidin-2-on-derivater som androgenreceptormodulatorer. DK2176220T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2007205966		2007-08-07
JP2007299658		2007-11-19
PCT/JP2008/064500 WO2009020234A2 (en)	2007-08-07	2008-08-06	Pyrrolidin-2 -one derivatives as androgen receptor modulator

Publications (1)

Publication Number	Publication Date
DK2176220T3 true DK2176220T3 (da)	2013-06-10

Family

ID=40329363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08792430.4T DK2176220T3 (da)	2007-08-07	2008-08-06	Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.

Country Status (34)

Country	Link
US (2)	US7834051B2 (da)
EP (1)	EP2176220B1 (da)
JP (1)	JP5292390B2 (da)
KR (1)	KR20100049644A (da)
CN (1)	CN101821235B (da)
AR (1)	AR067823A1 (da)
AU (1)	AU2008284662B2 (da)
BR (1)	BRPI0814957B8 (da)
CA (1)	CA2695852C (da)
CL (1)	CL2008002313A1 (da)
CO (1)	CO6160326A2 (da)
CR (1)	CR11266A (da)
CY (1)	CY1114067T1 (da)
DK (1)	DK2176220T3 (da)
DO (1)	DOP2010000053A (da)
EA (1)	EA017429B1 (da)
ES (1)	ES2406685T3 (da)
GE (1)	GEP20125571B (da)
HR (1)	HRP20130374T1 (da)
JO (1)	JO2864B1 (da)
MA (1)	MA31639B1 (da)
ME (1)	ME01579B (da)
MX (1)	MX2010001484A (da)
MY (1)	MY159910A (da)
NZ (1)	NZ583624A (da)
PE (1)	PE20090899A1 (da)
PL (1)	PL2176220T3 (da)
PT (1)	PT2176220E (da)
RS (1)	RS52812B (da)
SI (1)	SI2176220T1 (da)
TN (1)	TN2010000062A1 (da)
TW (1)	TWI418543B (da)
WO (1)	WO2009020234A2 (da)
ZA (1)	ZA201001289B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20090899A1 (es) *	2007-08-07	2009-08-06	Takeda Pharmaceutical	Derivados de aminobenceno como moduladores del receptor de androgeno
US8268872B2 (en) *	2008-02-22	2012-09-18	Radius Health, Inc.	Selective androgen receptor modulators
CA2716320C (en)	2008-02-22	2014-01-28	Radius Health, Inc.	Selective androgen receptor modulators
TW200944506A (en) *	2008-03-26	2009-11-01	Takeda Pharmaceutical	Substituted pyrazole derivatives and use thereof
CA2788907A1 (en)	2010-02-04	2011-08-11	Radius Health, Inc.	Selective androgen receptor modulators
EP3106159A1 (en)	2010-05-12	2016-12-21	Radius Health, Inc.	Therapeutic regimens
US8642632B2 (en)	2010-07-02	2014-02-04	Radius Health, Inc.	Selective androgen receptor modulators
JP5965909B2 (ja) *	2010-09-28	2016-08-10	ラジウスヘルス，インコーポレイテッド	選択的アンドロゲン受容体モジュレーター
US20150057452A1 (en) *	2012-04-04	2015-02-26	Catylix, Inc.	Selective androgen receptor modulators
EP3378472A1 (en) *	2012-08-09	2018-09-26	Dynamis Therapeutics, Inc.	Combinations of meglumine
US9868905B2 (en)	2012-09-21	2018-01-16	Merck Patent Gmbh	Compounds having a C—C triple bond and use thereof in liquid-crystal mixtures
CA2943611A1 (en)	2014-03-28	2015-10-01	Duke University	Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en)	2014-03-28	2016-08-23	Duke University	Method of treating cancer using selective estrogen receptor modulators
KR101597327B1 (ko) *	2014-04-24	2016-02-24	동아에스티 주식회사	옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
CN103951688B (zh) *	2014-05-06	2016-04-20	成都安斯利生物医药有限公司	一种制备3,5-二氟-4-甲基苯硼酸的方法
CA3027563C (en)	2016-06-22	2024-07-02	Ellipses Pharma Ltd	AR+ METHODS FOR BREAST CANCER TREATMENT
JP7481115B2 (ja)	2017-01-05	2024-05-10	ラジウスファーマシューティカルズ，インコーポレイテッド	Ｒａｄ１９０１－２ｈｃｌの多形性形態
IL279853B2 (en)	2018-07-04	2025-01-01	Radius Pharmaceuticals Inc	Polymorphic forms of RAD 1901-2HCL
TWI827785B (zh)	2019-01-11	2024-01-01	德商歌林達有限公司	經取代的吡咯啶醯胺iii
CN119390714A (zh)	2019-02-12	2025-02-07	雷迪厄斯制药公司	方法和化合物
CN110204505B (zh) *	2019-05-31	2023-02-03	荆门医药工业技术研究院	(s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺
US20230012570A1 (en) *	2019-11-20	2023-01-19	Medshine Discovery Inc.	Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4141399A1 (de) *	1991-12-16	1993-06-17	Bayer Ag	4-(substituierte)amino-3-arylpyrrolinon-derivate
PL346795A1 (en) *	1998-09-22	2002-02-25	Yamanouchi Pharma Co Ltd	Cyanophenyl derivatives
US6258833B1 (en)	1999-12-23	2001-07-10	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
US7026500B2 (en)	2000-08-24	2006-04-11	University Of Tennessee Research Foundation	Halogenated selective androgen receptor modulators and methods of use thereof
JP2002088073A (ja) *	2000-09-08	2002-03-27	Yamanouchi Pharmaceut Co Ltd	抗アンドロゲン剤
FR2817472B1 (fr)	2000-12-06	2003-01-03	Oreal	Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
EP1463497B1 (en)	2001-12-06	2011-10-05	GTX, Inc.	Treating muscle wasting with selective androgen receptor modulators
JP4316232B2 (ja)	2001-12-28	2009-08-19	武田薬品工業株式会社	アンドロゲン受容体拮抗剤
CA2471754A1 (en)	2001-12-28	2003-07-17	Takeda Chemical Industries, Ltd.	Androgen receptor antagonist
EP1534663A4 (en)	2002-06-17	2006-08-30	Univ Tennessee Res Foundation	N-BREAKDOWN SELECTIVE MODULATORS OF THE ANDROGEN RECEPTOR AND METHOD FOR THEIR USE
EP1553074B1 (en)	2002-08-12	2014-06-18	Takeda Pharmaceutical Company Limited	Fused benzene derivative and use
GB0402492D0 (en)	2004-02-04	2004-03-10	Pfizer Ltd	Pharmaceutically active compounds
US8519158B2 (en) *	2004-03-12	2013-08-27	Ligand Pharmaceuticals Incorporated	Androgen receptor modulator compounds and methods
BRPI0510808A (pt) *	2004-05-11	2007-11-06	Pfizer Prod Inc	derivados de benzonitrila para tratar fragilidade musculoesquelética
CN101248069A (zh)	2004-05-17	2008-08-20	阿卡蒂亚药品公司	雄激素受体调节剂及用其治疗疾病的方法
PL1753417T3 (pl)	2004-06-07	2012-09-28	Univ Tennessee Res Found	Selektywny modulator receptora androgenowego i jego zastosowania medyczne
RU2007130558A (ru)	2005-01-10	2009-02-20	Акэдиа Фармасьютикалз Инк. (Us)	Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов
TW200724139A (en) *	2005-05-05	2007-07-01	Warner Lambert Co	Androgen modulators
DE602006003432D1 (de)	2005-05-13	2008-12-11	Lilly Co Eli	Latoren des androgenrezeptors
JP5070054B2 (ja)	2005-08-01	2012-11-07	武田薬品工業株式会社	環状アミン化合物
EP1987827A1 (en)	2006-02-20	2008-11-05	Takeda Pharmaceutical Company Limited	Novel pharmaceutical
US20090156614A1 (en) *	2006-07-19	2009-06-18	Dalton James T	Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
RU2009106214A (ru)	2006-07-26	2010-09-10	Новартис АГ (CH)	Ингибиторы ундекапренилпирофосфатсинтазы
US8013008B2 (en) *	2006-11-30	2011-09-06	Takeda Pharmaceutical Company Limited	Cyclic amine compound
PE20090899A1 (es) *	2007-08-07	2009-08-06	Takeda Pharmaceutical	Derivados de aminobenceno como moduladores del receptor de androgeno

2008
- 2008-08-06 PE PE2008001314A patent/PE20090899A1/es not_active Application Discontinuation
- 2008-08-06 CL CL2008002313A patent/CL2008002313A1/es unknown
- 2008-08-06 TW TW097129774A patent/TWI418543B/zh not_active IP Right Cessation
- 2008-08-06 ES ES08792430T patent/ES2406685T3/es active Active
- 2008-08-06 CN CN2008801105925A patent/CN101821235B/zh not_active Expired - Fee Related
- 2008-08-06 HR HRP20130374AT patent/HRP20130374T1/hr unknown
- 2008-08-06 EP EP08792430A patent/EP2176220B1/en active Active
- 2008-08-06 BR BRPI0814957A patent/BRPI0814957B8/pt not_active IP Right Cessation
- 2008-08-06 JP JP2010504096A patent/JP5292390B2/ja not_active Expired - Fee Related
- 2008-08-06 RS RS20130235A patent/RS52812B/sr unknown
- 2008-08-06 AR ARP080103428A patent/AR067823A1/es unknown
- 2008-08-06 NZ NZ583624A patent/NZ583624A/en not_active IP Right Cessation
- 2008-08-06 ME MEP-2013-64A patent/ME01579B/me unknown
- 2008-08-06 PL PL08792430T patent/PL2176220T3/pl unknown
- 2008-08-06 SI SI200830941T patent/SI2176220T1/sl unknown
- 2008-08-06 MY MYPI2010000564A patent/MY159910A/en unknown
- 2008-08-06 CA CA2695852A patent/CA2695852C/en active Active
- 2008-08-06 EA EA201070246A patent/EA017429B1/ru unknown
- 2008-08-06 WO PCT/JP2008/064500 patent/WO2009020234A2/en not_active Ceased
- 2008-08-06 MX MX2010001484A patent/MX2010001484A/es active IP Right Grant
- 2008-08-06 GE GEAP200811715A patent/GEP20125571B/en unknown
- 2008-08-06 PT PT87924304T patent/PT2176220E/pt unknown
- 2008-08-06 US US12/221,739 patent/US7834051B2/en active Active
- 2008-08-06 AU AU2008284662A patent/AU2008284662B2/en not_active Ceased
- 2008-08-06 US US12/672,516 patent/US8420694B2/en not_active Expired - Fee Related
- 2008-08-06 DK DK08792430.4T patent/DK2176220T3/da active
- 2008-08-06 KR KR1020107005062A patent/KR20100049644A/ko not_active Abandoned
- 2008-08-09 JO JO2008353A patent/JO2864B1/en active
2010
- 2010-02-05 DO DO2010000053A patent/DOP2010000053A/es unknown
- 2010-02-05 TN TNP2010000062A patent/TN2010000062A1/fr unknown
- 2010-02-12 CR CR11266A patent/CR11266A/es unknown
- 2010-02-23 ZA ZA2010/01289A patent/ZA201001289B/en unknown
- 2010-02-26 MA MA32657A patent/MA31639B1/fr unknown
- 2010-03-05 CO CO10026475A patent/CO6160326A2/es unknown
2013
- 2013-06-21 CY CY20131100507T patent/CY1114067T1/el unknown

Also Published As

Publication number	Publication date
TWI418543B (zh)	2013-12-11
ZA201001289B (en)	2011-04-28
TW200916439A (en)	2009-04-16
TN2010000062A1 (en)	2011-09-26
SI2176220T1 (sl)	2013-05-31
CR11266A (es)	2010-03-22
CN101821235A (zh)	2010-09-01
US8420694B2 (en)	2013-04-16
MY159910A (en)	2017-02-15
KR20100049644A (ko)	2010-05-12
MX2010001484A (es)	2010-03-04
ME01579B (me)	2014-09-20
US20110098336A1 (en)	2011-04-28
US7834051B2 (en)	2010-11-16
AU2008284662B2 (en)	2013-07-25
GEP20125571B (en)	2012-07-10
MA31639B1 (fr)	2010-08-02
NZ583624A (en)	2012-06-29
AR067823A1 (es)	2009-10-21
BRPI0814957A2 (pt)	2015-02-03
WO2009020234A3 (en)	2009-04-16
EP2176220B1 (en)	2013-03-27
EA017429B1 (ru)	2012-12-28
PT2176220E (pt)	2013-04-09
BRPI0814957B8 (pt)	2021-05-25
EA201070246A1 (ru)	2010-08-30
CA2695852C (en)	2017-01-03
JP5292390B2 (ja)	2013-09-18
CL2008002313A1 (es)	2009-05-15
WO2009020234A2 (en)	2009-02-12
RS52812B (sr)	2013-10-31
CN101821235B (zh)	2012-11-14
DOP2010000053A (es)	2010-07-15
CY1114067T1 (el)	2016-07-27
US20090042967A1 (en)	2009-02-12
JO2864B1 (en)	2015-03-15
CA2695852A1 (en)	2009-02-12
PL2176220T3 (pl)	2013-08-30
CO6160326A2 (es)	2010-05-20
PE20090899A1 (es)	2009-08-06
ES2406685T3 (es)	2013-06-07
EP2176220A2 (en)	2010-04-21
JP2010535704A (ja)	2010-11-25
BRPI0814957B1 (pt)	2019-12-03
AU2008284662A1 (en)	2009-02-12
HRP20130374T1 (en)	2013-05-31
HK1143972A1 (en)	2011-01-21

Publication	Publication Date	Title
DK2176220T3 (da)	2013-06-10	Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.
DK2144897T3 (da)	2011-02-07	8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
DK2094658T3 (da)	2012-02-13	Tetrahydrocyclopenta[B]indolforbindelser som androgenreceptormodulatorer
DK2069335T3 (da)	2013-02-18	Pyridin-3-ylderivater som immunomoduleringsmidler
DK2300465T3 (da)	2019-06-24	Imidazopyridinderivater som hæmmere af receptortyrosinkinaser
BRPI0907844A2 (pt)	2018-01-30	moduladores seletivos do receptor de andrógeno
DK2132188T3 (da)	2012-02-27	Substituerede phenoxy-N-alkylerede thiazolidindioner som østrogenrelaterede receptor-alfa-modulatorer
DK2952177T3 (da)	2021-04-26	Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
DK2069336T3 (da)	2013-02-25	Pyridin-4-yl-derivater som immunomodulerende midler
DK2493858T3 (da)	2014-09-08	Androgenreceptor modulerende forbindelser.
BRPI0813653A2 (pt)	2014-12-30	Compostos de imidazotiazol moduladores de sirtuína
DK2195311T3 (da)	2011-05-23	Pyridinderivater som S1P1/EDG1-receptormodulatorer
BRPI0813651A2 (pt)	2014-12-30	Compostos de tiazolopiridina moduladores de sirtuína
DK1928845T3 (da)	2013-08-05	Aminodiazepiner som toll-lignende receptor-modulatorer
DK2224823T4 (da)	2022-02-21	Pulverformet carotinoidmiddel til farvning af drikkevarer
DK2262808T3 (da)	2013-11-04	Chemokinreceptormodulatorer
DK2297100T3 (da)	2012-12-17	Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
DK1984343T3 (da)	2013-03-25	2-substituerede benzimidazoler som selektive androgenreceptormodulatorer (SARMS)
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
DK2252609T3 (da)	2013-06-24	Pyridin-2-yl-derivater som immunomodulerende midler
DK2373652T3 (da)	2014-01-20	Substituerede piperidin-spiro-pyrrolidinon- og piperidinon-forbindelser anvendt som h3-modulatorer
BRPI0906714A2 (pt)	2015-06-30	Derivados de oxazepinopirimidona heteroarilamida substituídos.
DK2342182T3 (da)	2013-02-04	Isoquinolinonderivater som nk3-antagonister
BRPI0822061A2 (pt)	2015-06-23	Moduladores do receptor canabinoide
DK2099784T3 (da)	2013-01-14	1,5-diphenyl-3-pyridinylamino-1,5-dihydrioyrrolidin-2-on som cb1-receptor-modulatorer